



PATENT  
ATTY. DOCKET NO.: MBM1240

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Zhu et al.  
Serial No.: 09/927,110  
Filed: August 20, 2001  
Title: METHOD FOR INHIBITING INFLAMMATION IN IMMUNE  
PRIVILEGED SITES USING FAS LIGAND FRAGMENTS

Art Unit: 1645  
Examiner: Unassigned

RECEIVED

APR 01 2002

TECH CENTER 1600/2900

Box Sequence  
U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

STATEMENT UNDER 37 C.F.R. §§ 1.821(f) and (g)

Sir:

I hereby state, as required by 37 C.F.R. § 1.821(f), that the information recorded in computer readable form is identical to the written sequence listing.

I hereby state that the submission, filed in accordance with 37 C.F.R. § 1.821 (g), herein does not include new matter.

Respectfully submitted,

Date: February 21, 2002

By: Richard Reynolds <sup>Reg No</sup> 37,643  
Reg. No. P51,154  
Telephone: (858) 638-6724  
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1100  
San Diego, CA 92121-2133

Customer Number: 28213

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, <u>February 21, 2002</u> , in an envelope addressed to: U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327, Arlington, VA 22202.	
Mikhail Bayley	
Name of Person Mailing Paper	February 21, 2002
Signature	Date



PATENT  
ATTY. DOCKET NO.: MBM1240

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Zhu et al.  
Serial No.: 09/927,110  
Filed: August 20, 2001  
Title: METHOD FOR INHIBITING INFLAMMATION IN IMMUNE  
PRIVILEGED SITES USING FAS LIGAND FRAGMENTS

Art Unit: 1645  
Examiner: Unassigned

**Box Sequence**

U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

RECEIVED  
APR 01 2002  
TECH CENTER 1600/2900

**VERIFIED STATEMENT UNDER 37 C.F.R. § 1.821(f)**

Sir:

I, Mikhail Bayley, declare that I personally prepared the paper and the computer-readable copies of the Sequence Listing filed herewith in the above-entitled case and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


Date: 02/21/2002

Mikhail Bayley  
Mikhail Bayley

GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1100  
San Diego, CA 92121-2133

**Customer Number: 28213**

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, <u>February 21, 2002</u> , in an envelope addressed to: U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327, Arlington, VA 22202.	
<b>Mikhail Bayley</b>	
Name of Person Mailing Paper	February 21, 2002
Signature	Date



## SEQUENCE LISTING

&lt;110&gt; SEABRIGHT CORPORATION LIMITED

ZHU, Bing

CYNADER, Max

PATY, Donald

LUO, Liqing

<120> METHOD FOR INHIBITING INFLAMMATION IN IMMUNE PRIVILEGED SITES USING  
FAS LIGAND FRAGMENTS

&lt;130&gt; MBM1240

&lt;140&gt; US 09/927,110

&lt;141&gt; 2001-08-10

&lt;150&gt; US 60/224,016

&lt;151&gt; 2000-08-10

&lt;160&gt; 1

&lt;170&gt; PatentIn version 3.0

&lt;210&gt; 1

&lt;211&gt; 281

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

Met Gln Gln Pro Phe Asn Tyr Pro Tyr Pro Gln Ile Tyr Trp Val Asp  
1 5 10 15

Ser Ser Ala Ser Ser Pro Trp Ala Pro Pro Gly Thr Val Leu Pro Cys  
20 25 30

Pro Thr Ser Val Pro Arg Arg Pro Gly Gln Arg Arg Pro Pro Pro  
35 40 45

Pro Pro Pro Pro Pro Leu Pro Pro Pro Pro Pro Pro Pro Leu Pro  
50 55 60

Pro Leu Pro Leu Pro Pro Leu Lys Lys Arg Gly Asn His Ser Thr Gly  
65 70 75 80

Leu Cys Leu Leu Val Met Phe Phe Met Val Leu Val Ala Leu Val Gly  
85 90 95

Leu Gly Leu Gly Met Phe Gln Leu Phe His Leu Gln Lys Glu Leu Ala  
100 105 110

Glu Leu Arg Glu Ser Thr Ser Gln Met His Thr Ala Ser Ser Leu Glu  
115 120 125

Lys Gln Ile Gly His Pro Ser Pro Pro Pro Glu Lys Lys Glu Leu Arg  
130 135 140

Lys Val Ala His Leu Thr Gly Lys Ser Asn Ser Arg Ser Met Pro Leu  
145 150 155 160

Glu Trp Glu Asp Thr Tyr Gly Ile Val Leu Leu Ser Gly Val Lys Tyr  
165 170 175

RECEIVED  
APR 01 2002  
TECH CENTER 1600/2900

Lys Lys Gly Gly Leu Val Ile Asn Glu Thr Gly Leu Tyr Phe Val Tyr  
180 185 190

Ser Lys Val Tyr Phe Arg Gly Gln Ser Cys Asn Asn Leu Pro Leu Ser  
195 200 205

His Lys Val Tyr Met Arg Asn Ser Lys Tyr Pro Gln Asp Leu Val Met  
210 215 220

Met Glu Gly Lys Met Met Ser Tyr Cys Thr Thr Gly Gln Met Trp Ala  
225 230 235 240

Arg Ser Ser Tyr Leu Gly Ala Val Phe Asn Leu Thr Ser Ala Asp His  
245 250 255

Leu Tyr Val Asn Val Ser Glu Leu Ser Leu Val Asn Phe Glu Glu Ser  
260 265 270

Gln Thr Phe Phe Gly Leu Tyr Lys Leu  
275 280

---